Home›Stock Screener›Jagsonpal Pharmaceuticals›Financial Statements

Jagsonpal Pharmaceuticals Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Jagsonpal Pharmaceuticals (JAGSNPHARM) reported revenue ₹287 Cr, net profit ₹44 Cr and EPS ₹6.40, with a net profit margin of 15.3% and ROE of 15.9%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore Jagsonpal Pharmaceuticals intrinsic price to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 15.33% 2026 data
EBITDA Margin 19.51% 2026 data
Operating Margin 20.00% 2026 data
Return on Assets 13.88% 2026 data
Return on Equity 15.94% 2026 data

Balance Sheet Ratios

Current Ratio 11.92 2026 data
Equity Ratio 87.07% 2026 data
Asset Turnover 0.91 2026 data

JAGSNPHARM Revenue, Net Profit & EBITDA — Year-on-Year Growth

JAGSNPHARM YoY (March 2025 vs March 2026) — revenue +3.6%, net profit -20.0%, EBITDA -5.1%, expenses +6.0%. For live price, earnings ratios and company overview, see JAGSNPHARM stock price BSE.

Revenue Growth
+3.6%
Year-over-Year
Net Profit Growth
-20.0%
Year-over-Year
EBITDA Growth
-5.1%
Year-over-Year
Expense Growth
+6.0%
Year-over-Year
Assets Growth
+14.0%
Year-over-Year
Equity Growth
+15.0%
Year-over-Year
Operating Cash Flow Growth
+57.1%
Year-over-Year
Investing Cash Flow Growth
-80.0%
Year-over-Year
Financing Cash Flow Growth
-33.3%
Year-over-Year

JAGSNPHARM Income Statement — Revenue, EBITDA & Net Profit

Jagsonpal Pharmaceuticals revenue ₹287 Cr, EBITDA ₹56 Cr, net profit ₹44 Cr, EPS ₹6.40 (2026) — net profit margin 15.3%. Review JAGSNPHARM price earnings ratio to evaluate earnings-based valuation against sector peers.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 287 277 218 242 221 192 161 168 127 144 144 138
Expenses 231 218 186 203 193 169 150 158 138 138 132 129
EBITDA 56 59 32 40 29 24 11 11 -11 6 13 9
Operating Profit Margin % 20.00% 19.00% 11.00% 14.00% 12.00% 10.00% 5.00% 6.00% -9.00% 4.00% 8.00% 6.00%
Depreciation 9 8 2 1 2 1 1 1 0 2 3 3
Interest 1 1 1 0 0 1 1 1 1 3 5 5
Profit Before Tax 58 70 30 35 27 22 9 9 -12 14 4 2
Tax 13 15 7 8 8 5 2 2 0 3 1 1
Net Profit 44 55 23 27 19 17 8 7 -12 12 3 1
Earnings Per Share (₹) 6.40 8.26 3.40 10.20 7.20 6.51 3.00 2.75 -4.41 4.53 1.24 0.45

JAGSNPHARM Balance Sheet — Assets, Liabilities & Shareholders' Equity

JAGSNPHARM total assets ₹317 Cr, total equity ₹276 Cr, total liabilities ₹ Cr (2026) — ROE 15.9%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 317 278 217 195 164 164 147 136 130 143 159 154
Current Assets 143 161 197 165 109 121 95 98 95 110 101 96
Fixed Assets 85 95 9 24 23 26 22 22 21 22 52 52
Capital Work in Progress 0 0 0 0 0 0 4 4 3 0 0 0
Investments 15 0 0 1 51 15 11 0 0 0 0 0
Other Assets 0 184 208 170 91 123 109 110 106 121 108 102
LIABILITIES
Total Liabilities
Current Liabilities 12 12 11 9 5 2 3 3 3 3 4 4
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 276 240 187 159 133 122 111 105 98 110 98 95
Share Capital 13 13 13 13 13 13 13 13 13 13 13 13
Reserves & Surplus 263 226 174 146 120 109 98 91 85 97 85 82

JAGSNPHARM Cash Flow Statement — Operating, Investing & Financing

Jagsonpal Pharmaceuticals operating cash flow ₹55 Cr, investing ₹-45 Cr, financing ₹-12 Cr, net cash flow ₹-2 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 55 35 47 7 28 11 31 -2 -3 9 4
Investing Activities -45 -25 -58 -26 -2 -11 -1 -3 41 -2 -1
Financing Activities -12 -9 -1 -18 -7 -1 -6 -1 -34 -6 -1
Net Cash Flow -2 2 -12 -36 19 -1 24 -6 5 1 2